Synuca Therapeutics ApS
CVR 45367282 · Private limited company (ApS) · Active · Medium risk
Synuca Therapeutics ApS is a Private limited company (ApS), founded on , based in København N. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 1.4% over the next 12 months, which is 1.0 times the average for Danish companies. 1 annual report has been published. The latest annual report (31 Dec 2025) shows equity of DKK -267k and a net result of DKK -273k. CEO: William Brown, Lasse Reimer.
Bankruptcy risk for Synuca Therapeutics ApS
1.0 × the average (1.41%) · higher risk than 77% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 45367282
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (1 years)
- Address
- Ole Maaløes Vej 3
2200 København N - Municipality
- København
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 40k
- Auditor
- EY Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 1 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -77.6% |
| Current ratio | 636% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 0 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 167 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 |
|---|---|
| Gross profit | DKK -256k |
| Net profit | DKK -273k |
| Equity | DKK -267k |
| Total assets | DKK 345k |
| Cash | DKK 267k |
| Short-term debt | DKK 54k |
| Avg. employees | 1 |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · EY Godkendt Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 30 Jan 2025 – 31 Dec 2025 | 180 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | William Brown | Current | |
| CEO | Lasse Reimer | Current | |
| Board | Claus Elsborg Olesen | Current | |
| Board | Anker Gunvald Lundemose | Current | |
| Board | Lasse Reimer | Current | |
| Owner (25%) | CLAUS OLESEN HOLDING ApS | Current | |
| Owner (25%) | BODD ApS | Current | |
| Owner (15%) | PHJ 2025 Holding ApS | Current | |
| Owner (15%) | Raul Holding ApS | Current | |
| Owner (20%) | PHJ 2025 Holding ApS | ||
| Owner (20%) | Raul Holding ApS | ||
| Auditor | EY Godkendt Revisionspartnerselskab | Current | |
| Founder | CLAUS OLESEN HOLDING ApS | Current | |
| Founder | BODD ApS | Current | |
| Founder | PHJ 2025 Holding ApS | Current | |
| Founder | Raul Holding ApS | Current |
The CEOs' other companies
William Brown – 2 other companies
- BODD ApS Active
- CaDo Biotechnology IvS Opløst
Lasse Reimer – 1 other companies
- Raul Holding ApS Active
Address history (0 moves)
| Ole Maaløes Vej 3, 2200 København N |
Other companies at the same address
- 25-06-2019 ApS Bankrupt
- Ankrin Therapeutics ApS Bankrupt
- Avineuro ApS Bankrupt
- BIOREPELLER IVS Bankrupt
- Bainan Biotech ApS Bankrupt
- Broselid Holding IVS Bankrupt
- ChildTreat ApS Bankrupt
- Dencomm ApS Bankrupt
- IO BIOTECH ApS Bankrupt
- Invitreo Biosciences ApS Bankrupt
- Lab Hos Development ApS Bankrupt
- MGM BIO IVS Bankrupt
- Mind the Byte ApS Bankrupt
- PanCryos ApS Bankrupt
- Ressaissi Holding IVS Bankrupt
- SSIP 2023 ApS Bankrupt
- Spit Test Company ApS Bankrupt
- Sterisafe Holding A/S Bankrupt
- Sumondo ApS Bankrupt
- TychoBio IVS Bankrupt
- aiwell Nordic ApS Bankrupt
- 1stBiome ApS Active
- 3Sonic ApS Active
- 55 North General Partner I ApS Active
- 55 North Management ApS Active
Similar companies in København
- AffiCon ApS Valby
- EXTITUTION ApS København Ø
- Coco Sense ApS København NV
- Everllence Denmark A/S København SV
- BioSpectre ApS København V
- Nordic Cell Therapy Group ApS København N
- FiberSure ApS København Ø
- Tasira ApS København N
- Xenogen ApS København S
- Magnalev Core ApS København SV
- Pin Joint ApS København S
- Maglya ApS København Ø
Questions and answers about Synuca Therapeutics ApS
Has Synuca Therapeutics ApS gone bankrupt?
No, Synuca Therapeutics ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Synuca Therapeutics ApS?
Our model estimates a bankruptcy risk of 1.4% over the next 12 months (medium risk), which is 1.0 times the average for Danish companies.
Who is the CEO of Synuca Therapeutics ApS?
William Brown, Lasse Reimer are the CEOs of Synuca Therapeutics ApS.
Who is the auditor of Synuca Therapeutics ApS?
Synuca Therapeutics ApS most recently used EY Godkendt Revisionspartnerselskab.
When was Synuca Therapeutics ApS founded?
Synuca Therapeutics ApS was founded on 30 January 2025.
What is the equity of Synuca Therapeutics ApS?
Equity was DKK -267k according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.